Right now, only one company is trying to develop a new type of cell therapy for cancer: Iovance Biotherapeutics, with a market cap of $1.3 billion and 80 employees, and $246 million in the bank.
Does Tiny Iovance Deserve To Ride The T-Cell Wave?
Right now, only one company is trying to develop a new type of cell therapy for cancer: Iovance Biotherapeutics, with a market cap of $1.3 billion and 80 employees, and $246 million in the bank.